The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonist: Results of a Phase III, single‐dose trial versus dolasetron
Open accessAbstract
BACKGROUND: Palonosetron, a highly selective and potent 5‐HT 3 receptor antagonist with a strong binding affinity and a long plasma elimination half‐life (approximately 40 hours), has shown efficacy in Phase II trials in preventing chemotherapy‐induced nausea and vomiting (CINV) resulting from highly emetogenic chemotherapy. The current Phase III trial evaluated the efficacy and safety of palonosetron in preventing acute and delayed CINV after moderately emetogenic chemotherapy. METHODS: In the current study, 592 patients were randomized to receive a single, intravenous dose of palonosetron 0.25 mg, palonosetron 0.75 mg, or dolasetron 100 mg, 30 minutes before receiving moderately emetogenic chemotherapy. The primary efficacy endpoint was the proportion of patients with a complete response (CR; defined as no emetic episodes and no rescue medication) during the first 24 hours after chemotherapy. Secondary endpoints included assessment of prevention of delayed emesis (2–5 days postchemotherapy). RESULTS: In the current study, 569 patients received study medication and were included in the intent‐to‐treat efficacy analyses. CR rates during the first 24 hours were 63.0% for palonosetron 0.25 mg, 57.1% for palonosetron 0.75 mg, and 52.9% for dolasetron 100 mg. CR rates during the delayed period (24–120 hours after chemotherapy) were superior for palonosetron compared with dolasetron. Adverse events (AEs) were mostly mild to moderate and not related to study medication, with similar incidences among groups. There were no serious drug‐related AEs. CONCLUSIONS: A single dose of palonosetron is as effective as a single dose of dolasetron in preventing acute CINV and superior to dolasetron in preventing delayed CINV after moderately emetogenic chemotherapy, with a comparable safety profile for all treatment groups. Cancer 2003. © 2003 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
Gralla, R. J., Osoba, D., Kris, M. G., Kirkbride, P., Hesketh, P. J., Chinnery, L. W., Clark-Snow, R., Gill, D. P., Groshen, S., Grunberg, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2971 · Cited by 664
Self-citationDCS (1999) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/56.8.729 · Cited by 281
Quality of life consequences of chemotherapy-induced emesis
Lindley, C. M., Hirsch, J. D., O'Neill, C. V., Transau, M. C., Gilbert, C. S., & Osterhaus, J. T. (1992) · Quality of Life Research · doi:10.1007/bf00434947 · Cited by 257
The interaction of RS 25259‐197, a potent and selective antagonist, with 5‐HT3 receptors, in vitro
Wong, E. H. F., Clark, R. D., Leung, E., Loury, D. J., Bonhaus, D. W., Jakeman, L. B., Parnes, H. L., Whiting, R. L., & Eglen, R. M. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb13282.x · Cited by 169
Hesketh, P. J. (2000) · Cancer Investigation · doi:10.3109/07357900009038248 · Cited by 159
Kaizer, L., Warr, D. G., Hoskins, P. J., Latreille, J., Lofters, W., Yau, J., Palmer, M. K., Zee, B. C.-Y., Levy, M., & Pater, J. L. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.5.1050 · Cited by 115
Antiemetic guidelines: creating a more practical treatment approach
Koeller, J. M., Aapro, M., Gralla, R. J., Grunberg, S. M., Hesketh, P. J., Kris, M. G., & Clark-Snow, R. A. (2002) · Supportive Care in Cancer · doi:10.1007/s00520-001-0335-y · Cited by 111
Self-citationBalfour, J. A. B., & Goa, K. L. (1997) · Drugs · doi:10.2165/00003495-199754020-00008 · Cited by 67
Potential role of the NK 1 receptor antagonists in chemotherapy-induced nausea and vomiting
Hesketh, P. J. (2001) · Supportive Care in Cancer · doi:10.1007/s005200000199 · Cited by 52
Cited by
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting
Navari, R. M., & Aapro, M. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1515442 · Cited by 477
Cancer cachexia—pathophysiology and management
Suzuki, H., Asakawa, A., Amitani, H., Nakamura, N., & Inui, A. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0787-0 · Cited by 268
Shahid, F., Farooqui, Z., & Khan, F. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.009 · Cited by 166
Jordan, K., Hinke, A., Grothey, A., Voigt, W., Arnold, D., Wolf, H.-H., & Schmoll, H.-J. (2007) · Supportive Care in Cancer · doi:10.1007/s00520-006-0186-7 · Cited by 93
Metadata
- Authors
- Eisenberg, P., Figueroa‐Vadillo, J., Zamora, R., Charu, V., Hajdenberg, J., Cartmell, A., Macciocchi, A., & Grunberg, S.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-11-17
- Volume
- 98
- Issue
- 11
- Pages
- 2473-2482
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1973339347
- Cited by
- 400
- References
- 9
- FWCI
- 17.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonist: Results of a Phase III, single‐dose trial versus dolasetron. https://app.cochat.ai/papers/10.1002/cncr.11817
- The paper
- Eisenberg, P., Figueroa‐Vadillo, J., Zamora, R., Charu, V., Hajdenberg, J., Cartmell, A., Macciocchi, A., & Grunberg, S. (2003). Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonist: Results of a Phase III, single‐dose trial versus dolasetron. Cancer. https://doi.org/10.1002/cncr.11817
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
